Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

673.45INR
3:11am EST
Change (% chg)

Rs-6.15 (-0.90%)
Prev Close
Rs679.60
Open
Rs681.00
Day's High
Rs684.70
Day's Low
Rs671.00
Volume
147,417
Avg. Vol
466,021
52-wk High
Rs898.00
52-wk Low
Rs572.40

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.27
Market Cap(Mil.): Rs1,630,678.00
Shares Outstanding(Mil.): 2,399.29
Dividend: 1.00
Yield (%): 0.15

Financials

  SUN.BO Industry Sector
P/E (TTM): 22.00 28.47 29.39
EPS (TTM): 30.89 -- --
ROI: -- 13.57 13.06
ROE: -- 14.45 14.19

BRIEF-Sun Pharmaceutical Industries says European Medicines Agency approves Tobramycin

* Sun Pharmaceutical Industries clarifies on news item "UK regulator approves Sun Pharma generic drug of Tobramycin"

Feb 16 2017

Morning News Call - India, February 15

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_02152017.pdf If you would like to receive this newsletter via email, please register at: https://forms.thomsonreuters.com/india-morning/ FACTORS TO WATCH 10:00 am: Power Minister Piyush Goyal and Mines Secretary Balvinder Kumar at national conclave on mines and minerals 2017 in New Delhi. 11:30 am: India Ratings briefs media on macroeconomic

Feb 14 2017

Sun Pharma's profits drop as U.S. sales hit by pricing, supply issues

MUMBAI Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market.

Feb 14 2017

UPDATE 2-Sun Pharma's profits drop as U.S. sales hit by pricing, supply issues

* Q3 U.S. sales up 4 pct, India sales up 5 pct (Adds CEO's comments made in conference call with analysts)

Feb 14 2017

BRIEF-Sun Pharmaceutical Industries exec says co expects to be able to address Halol issues over next few qtrs

* Exec says expects to be able to address Halol issues over the next few quarters

Feb 14 2017

India's Sun Pharma Q3 profit falls nearly 5 pct; below estimates

MUMBAI, Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd's third-quarter profit fell below analysts' estimates due to slower sales in the United States, its largest market.

Feb 14 2017

BRIEF-Sun Pharmaceutical Industries Q3 India sales up by 5 pct

* Says Q3 india sales at inr 19.69 billion, up by 5% over q3 last year

Feb 14 2017

BRIEF-Sun Pharmaceutical Dec-qtr consol profit down about 5 pct

* Dec quarter consol total income from operations 79.13 billion rupees

Feb 14 2017

U.S. states sue Mylan, Teva, others for fixing drug prices

WASHINGTON Two years after high generic drug prices became a public controversy, legal cases are starting to land.

Dec 15 2016

FDA finds quality control problems at Sun Pharma's Halol plant

MUMBAI The U.S. Food and Drug Administration (FDA) has again raised concerns about the quality control process at Indian drugmaker Sun Pharmceutical Industries' Halol factory, an inspection report obtained by Reuters shows.

Dec 13 2016

More From Around the Web

Earnings vs. Estimates